Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 436

1.

A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.

Kishimoto M, Noda M.

Cardiovasc Diabetol. 2011 Dec 22;10:115. doi: 10.1186/1475-2840-10-115.

PMID:
22189184
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.

Aoki K, Kamiyama H, Yoshimura K, Shibuya M, Masuda K, Terauchi Y.

Acta Diabetol. 2012 Jun;49(3):225-30. doi: 10.1007/s00592-011-0322-9. Epub 2011 Sep 6. Erratum in: Acta Diabetol. 2012 Jun;49(3):231.

PMID:
21898126
[PubMed - indexed for MEDLINE]
3.

Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.

Imai C, Saito M, Mochizuki K, Fuchigami M, Goda T, Osonoi T.

Metabolism. 2014 Jun;63(6):746-53. doi: 10.1016/j.metabol.2013.12.014. Epub 2014 Jan 7.

PMID:
24559582
[PubMed - indexed for MEDLINE]
4.

Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men.

Aoki K, Masuda K, Miyazaki T, Togashi Y, Terauchi Y.

Endocr J. 2010;57(8):667-72. Epub 2010 Jun 1. Erratum in: Endocr J. 2010;57(12):1089.

PMID:
20519806
[PubMed - indexed for MEDLINE]
Free Article
5.

Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA.

J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9. Epub 2006 Aug 15.

PMID:
16912128
[PubMed - indexed for MEDLINE]
6.

Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus.

Nagai E, Katsuno T, Miyagawa J, Konishi K, Miuchi M, Ochi F, Kusunoki Y, Tokuda M, Murai K, Hamaguchi T, Namba M.

Endocr J. 2011;58(10):869-77. Epub 2011 Aug 26.

PMID:
21869539
[PubMed - indexed for MEDLINE]
Free Article
7.

Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.

Garg SK, Moser EG, Bode BW, Klaff LJ, Hiatt WR, Beatson C, Snell-Bergeon JK.

Endocr Pract. 2013 Jan-Feb;19(1):19-28. doi: 10.4158/EP12100.OR.

PMID:
23186950
[PubMed - indexed for MEDLINE]
8.

The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.

Lee A, Patrick P, Wishart J, Horowitz M, Morley JE.

Diabetes Obes Metab. 2002 Sep;4(5):329-35.

PMID:
12190996
[PubMed - indexed for MEDLINE]
9.

Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).

Sakamoto M, Nishimura R, Irako T, Tsujino D, Ando K, Utsunomiya K.

Cardiovasc Diabetol. 2012 Aug 6;11:92. doi: 10.1186/1475-2840-11-92.

PMID:
22867630
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.

Zambrowicz B, Ding ZM, Ogbaa I, Frazier K, Banks P, Turnage A, Freiman J, Smith M, Ruff D, Sands A, Powell D.

Clin Ther. 2013 Mar;35(3):273-285.e7. doi: 10.1016/j.clinthera.2013.01.010. Epub 2013 Feb 21.

PMID:
23433601
[PubMed - indexed for MEDLINE]
11.

Effects of miglitol versus sitagliptin on postprandial glucose and lipoprotein metabolism in patients with type 2 diabetes mellitus.

Okada K, Yagyu H, Kotani K, Yamazaki H, Ozaki K, Takahashi M, Nagashima S, Osuga J, Ishibashi S.

Endocr J. 2013;60(7):913-22. Epub 2013 Apr 10.

PMID:
23574730
[PubMed - indexed for MEDLINE]
Free Article
12.

Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy.

Mori Y, Taniguchi Y, Miyazaki S, Yokoyama J, Utsunomiya K.

Diabetes Technol Ther. 2013 Mar;15(3):237-40. doi: 10.1089/dia.2012.0214. Epub 2013 Feb 12.

PMID:
23402316
[PubMed - indexed for MEDLINE]
13.

Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose.

Vardarli I, Arndt E, Deacon CF, Holst JJ, Nauck MA.

Diabetes. 2014 Feb;63(2):663-74. doi: 10.2337/db13-0805. Epub 2013 Nov 1.

PMID:
24186866
[PubMed - indexed for MEDLINE]
Free Article
14.

Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring.

Mori Y, Taniguchi Y, Matsuura K, Sezaki K, Yokoyama J, Utsunomiya K.

Diabetes Technol Ther. 2011 Jul;13(7):699-703. doi: 10.1089/dia.2011.0025. Epub 2011 Apr 19.

PMID:
21504334
[PubMed - indexed for MEDLINE]
15.

Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.

Guerci B, Monnier L, Serusclat P, Petit C, Valensi P, Huet D, Raccah D, Colette C, Quéré S, Dejager S.

Diabetes Metab. 2012 Oct;38(4):359-66. doi: 10.1016/j.diabet.2012.06.001. Epub 2012 Jul 17.

PMID:
22809630
[PubMed - indexed for MEDLINE]
Free Article
16.

The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study.

Stevens JE, Horowitz M, Deacon CF, Nauck M, Rayner CK, Jones KL.

Aliment Pharmacol Ther. 2012 Aug;36(4):379-90. doi: 10.1111/j.1365-2036.2012.05198.x. Epub 2012 Jun 28.

PMID:
22738299
[PubMed - indexed for MEDLINE]
17.

Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.

Aaboe K, Knop FK, Vilsbøll T, Deacon CF, Holst JJ, Madsbad S, Krarup T.

Diabetes Obes Metab. 2010 Apr;12(4):323-33. doi: 10.1111/j.1463-1326.2009.01167.x.

PMID:
20380653
[PubMed - indexed for MEDLINE]
18.

Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials.

Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP.

Curr Med Res Opin. 2008 Feb;24(2):489-96. doi: 10.1185/030079908X261069 . Review.

PMID:
18182122
[PubMed - indexed for MEDLINE]
19.

Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus.

Stephens JW, Bodvarsdottir TB, Wareham K, Prior SL, Bracken RM, Lowe GD, Rumley A, Dunseath G, Luzio S, Deacon CF, Holst JJ, Bain SC.

Diabetes Res Clin Pract. 2011 Nov;94(2):199-206. doi: 10.1016/j.diabres.2011.07.014. Epub 2011 Aug 10.

PMID:
21835486
[PubMed - indexed for MEDLINE]
20.

Effect of miglitol as an add-on to bolus insulin on postprandial glycemic excursions in type 2 diabetes patients assessed by continuous glucose monitoring.

Matsuura K, Mori Y, Nakamura A, Yokoyama J, Utsunomiya K.

Diabetes Technol Ther. 2012 May;14(5):423-9. doi: 10.1089/dia.2011.0188. Epub 2012 Feb 8.

PMID:
22316114
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk